Effect of Pitavastatin on restenosis with carotid artery stenting

Effect of Pitavastatin on restenosis with carotid artery stenting - Effect of Pitavastatin on restenosis with carotid artery stenting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005501

Enrollment

Registered

2011-04-25

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled carotid artery stenting

Interventions

Pitavastatin 4 mg daily Pitavastatin 1 mg daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients scheduled carotid artery stenting 2.Hypercholesterolemia patients Meeting one of following criteria 1)TC is 220 mg/dL or over 2)LDL-C is 140 mg/dL or over 3)LDL-C is 120 mg/dL or over or TC is 200 mg/dL or over and requiring cholesterol lowering drugs judged by attending physicians 4) Patients given written informed consent 3.Age (20<= <85 year-old) 4.Patients given written informed consent

Exclusion criteria

Exclusion criteria: 1.Malignant tumor in active phase 2.Patients who meet contraindication of LIVALO tablet below 1)Patients who have hypersensitivity to LIVALO tablet 2)Patients who have severe liver dysfunction or biliary atresia 3)Patients who are being treated with cyclosporine 4)Pregnant women, women suspected of being pregnant, or lactating women 3.Patients with hypersensitive to contrast media 4.Patients with liver dysfunction [ALT(GPT) 100 IU/L <=] 5.Patients undergoing dialysis 6.Patients with familial hypercholesterolemia 7.Patients who are ineligible in the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
The change of carotid artery plaque volume at carotid artery stent region using MDCT	—

Secondary

Measure	Time frame
1.Max IMT at carotid artery stent region and common carotid artery in ipsilateral side using echo 2.Max IMT at other side of carotid artery stent region using echo 3.The changes in TC, LDL-C, TG, HDL-C, non-HDL-C, LDL-C/HDL-C, RLP-C and MDA-LDL 4.The correlation between change in lipid profiles and change in max IMT at carotid artery stent region and common carotid artery in ipsilateral side 5.The correlation between change in lipid profiles and change in max IMT at other side of carotid artery stent region 6.Change in inflammation marker (CRP, SAA) 7.The correlation between Changes in inflammation marker and change in max IMT at carotid artery stent region and common carotid artery in ipsilateral side 8.The correlation between Changes in inflammation marker and change in max IMT at other side of carotid artery stent region 9.The incidence rate of adverse event 10.The changes in laboratory values	—

Measure

Time frame

1.Max IMT at carotid artery stent region and common carotid artery in ipsilateral side using echo 2.Max IMT at other side of carotid artery stent region using echo 3.The changes in TC, LDL-C, TG, HDL-C, non-HDL-C, LDL-C/HDL-C, RLP-C and MDA-LDL 4.The correlation between change in lipid profiles and change in max IMT at carotid artery stent region and common carotid artery in ipsilateral side 5.The correlation between change in lipid profiles and change in max IMT at other side of carotid artery stent region 6.Change in inflammation marker (CRP, SAA) 7.The correlation between Changes in inflammation marker and change in max IMT at carotid artery stent region and common carotid artery in ipsilateral side 8.The correlation between Changes in inflammation marker and change in max IMT at other side of carotid artery stent region 9.The incidence rate of adverse event 10.The changes in laboratory values

—

Countries

Japan

Contacts

Public ContactKiura Y

Hiroshima University hospital Neurosurgery

082-257-5555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026